Claims
- 1. 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1
- 2. The compound according to claim 1, wherein the compound is present in the form of one of its hydrates.
- 3. The compound according to claim 1, wherein the compound is present in the form of its monohydrate.
- 4. The compound according to claim 1, wherein the compound is present in the form of its hemihydrate.
- 5. A pharmaceutical composition comprising:
(a) the compound according to claim 1; and (b) a pharmaceutically acceptable excipient.
- 6. A pharmaceutical composition comprising:
(a) the compound according to claim 2; and (b) a pharmaceutically acceptable excipient.
- 7. A pharmaceutical composition comprising:
(a) the compound according to claim 3; and (b) a pharmaceutically acceptable excipient.
- 8. A pharmaceutical composition comprising:
(a) the compound according to claim 4; and (b) a pharmaceutically acceptable excipient.
- 9. A method of treating diseases in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 1.
- 10. A method of treating diseases in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 2.
- 11. A method of treating diseases in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 3.
- 12. A method of treating diseases in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 4.
- 13. The method according to claim 9, wherein the compound according to claim 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.
- 14. The method according to claim 10, wherein the compound according to claim 2 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.
- 15. The method according to claim 11, wherein the compound according to claim 3 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.
- 16. The method according to claim 12, wherein the compound according to claim 4 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.
Priority Claims (1)
Number |
Date |
Country |
Kind |
101 06 970.7 |
Feb 2001 |
DE |
|
Related Applications
[0001] Benefit under 35 U.S.C. §119(e) of prior provisional application Serial No. 60/281,344, filed Apr. 4, 2001, is hereby claimed.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60281344 |
Apr 2001 |
US |